PLYMOUTH, MN – January 11, 2017 - Cantel Medical Corp. (NYSE:CMD) is pleased to announce that its subsidiary, Mar Cor Purification, a market leader in purified water systems, has entered into an agreement with RephiLe Biosciences, Ltd. to distribute their laboratory water systems to customers in North America. These systems are used in research facilities, universities, hospitals and other critical high purity, low volume applications. The broad line of systems are capable of producing various grades of high purity water used in lab, research, blood analyzers and other grades of water.
“The RephiLe line of laboratory systems are designed to meet the increasing requirements of our customers by providing technically advanced, innovative systems coupled with a robust design,” stated Christopher Fournier, VP Marketing, Mar Cor. “Our direct sales force of over 50 professional sales people will have full access to the entire product line in order to address the specialized capacity requirements of the laboratory market.”
Peter Lucas, President, North America, RephiLe Biosciences stated, “Mar Cor provides unparalleled support to its water purification customers from a sales and service perspective. With Mar Cor’s 30 service and regeneration centers across North America, coupled with experienced sales and service teams, our customers will have coverage for installation, service, and maintenance of RephiLe Biosciences water purification systems. This agreement continues to build upon our strategic and tactical expansion in North America to offer our customers outstanding products and support.”
About Cantel Medical
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products.
For further information, visit the Cantel website at www.cantelmedical.com
About Mar Cor Purification, Inc.
Mar Cor Purification, Inc., a wholly-owned subsidiary of Cantel Medical Corp. (NYSE: CMN), is a water purification company and is the largest supplier of dialysis medical water systems in North America. It has service facilities in 30 cities in the United States and Canada including nine ion exchange resin regeneration plants strategically located in large metropolitan areas. Mar Cor also provides turnkey water purification systems to high purity clients including pharmaceutical, cosmetics, semiconductor and other bacteria controlled applications. Unique hollow fiber filtration/separation products and Peracetic acid (PAA) disinfectants are provided through a worldwide distributor network.
Visit our website at www.mcpur.com to find out more about Mar Cor Purification.
About RephiLe BioScience
RephiLe Bioscience Ltd. is a global company that designs and manufactures innovative and high quality purification based products for biotechnology and life science laboratories. Our offering includes pure water systems and consumables, and other filtration and purification based products. Our water technology platforms include the most advanced technologies and continuous electro-deionization (CEDI) technologies to meet the needs of various laboratories and pilot production requirements: high product water quality that meets or exceeds ASTM, CLSI and CAP standards, stable performance, easy to manage at economical.
Our customer base encompasses government certification agencies, QC labs and GMP plants of pharmaceutical companies, laboratories in research institutes and universities, hospital laboratories, and environmental testing facilities. We look forward to serving our customers´ future needs with an ever-expanding range of products and services. For more information, contact us at: email@example.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.